Medilabo Rfp Inc vs The Controller Of Patents

ik-194784346 Delhi High Court 24 November 2025 • 26 min read

Judges (1)

Tejas Karia Delivered

Counsel (5)

Ankush Verma Counsel Appellant Debashish Banerjee Counsel Appellant Nishant Gautam Counsel Respondent Prithviraj Dey Counsel Respondent Vaishali Joshi Counsel Appellant

Parties (2)

Medilabo RFP Inc Appellant The Controller of Patents Respondent

Case Significance

Medilabo Rfp Inc vs The Controller Of Patents is a Delhi High Court decision dated November 24, 2025 (citation: ik-194784346). Japanese pharmaceutical company Medilabo RFP Inc appealed the refusal of its patent application for a neurodegenerative disease drug composition involving rifampicin and resveratrol administered through trans-nasal delivery, rejected under Section 3(i) of the Patents Act as a mere admixture. The Court found that the Controller failed to adequately consider the synergistic effect of the combination and the specific mode of administration, and also failed to address other pending objections und The case was heard by Justice Tejas Karia. Counsel appearing: Ankush Verma (counsel for appellant), Debashish Banerjee (counsel for appellant), Nishant Gautam (counsel for respondent), Prithviraj Dey (counsel for respondent), Vaishali Joshi (counsel for appellant).

Summary

Japanese pharmaceutical company Medilabo RFP Inc appealed the refusal of its patent application for a neurodegenerative disease drug composition involving rifampicin and resveratrol administered through trans-nasal delivery, rejected under Section 3(i) of the Patents Act as a mere admixture. The Court found that the Controller failed to adequately consider the synergistic effect of the combination and the specific mode of administration, and also failed to address other pending objections under Sections 2(1)(ja), 59, and 3(d). The appeal was allowed, the refusal order set aside, and the application remanded for fresh consideration including amended claims within six months.

What was the outcome of Medilabo Rfp Inc vs The Controller Of Patents?

Japanese pharmaceutical company Medilabo RFP Inc appealed the refusal of its patent application for a neurodegenerative disease drug composition involving rifampicin and resveratrol administered throu...

Judgment

Read the full judgment on the official India Courts portal.

Read on Indian Kanoon

Source: Indian Kanoon (ik-194784346)